I7P-MC-DSAG Ulcerative Colitis Study
An adaptive, dose-ranging, Phase 2 study of eltrekibart and mirikizumab for the treatment of adult patients with moderately to severely active ulcerative colitis
Site Resources
Thank you for being a site for theI7P-MC-DSAG Ulcerative Colitis Study.
Eltrekibart is a humanized monoclonal antibody that acts on pathways that modulate neutrophil migration and angiogenesis. Neutrophils are critical to the pathogenesis of ulcerative colitis.
Eltrekibart’s unique and potentially complementary mechanism provides the rationale for studying the treatment alone and in combination with mirikizumab.
This website is a place for site resources.